16:13:24 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-31 Årsstämma 2024
2024-03-29 Bokslutskommuniké 2023
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-31 Årsstämma 2023
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-02 Ordinarie utdelning BIOSGN 0.00 SEK
2023-03-31 Bokslutskommuniké 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-06-30 Årsstämma 2022
2022-05-31 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning BIOSGN 0.00 SEK
2022-03-31 Bokslutskommuniké 2021
2021-11-30 Kvartalsrapport 2021-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Biosergen är verksamt inom bioteknik. Bolaget är specialiserat inom forskning och utveckling av diverse läkemedel. Produktportföljen inkluderar exempelvis bolagets produkt BSG005, ett svampdödande läkemedel i klinisk fas. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs i Norge. Biosergen grundades år 2004 och har sitt huvudkontor i Solna.
2023-08-22 07:55:41

Stockholm, Sweden - August 22, 2023 - Today is the last day of trading in warrants series TO2 in Biosergen AB ("Biosergen" or the "Company"). The exercise period for the warrants series TO2 runs up until August 25, 2023. Each warrant series TO2 gives the owner the right to subscribe for one (1) new share in the Company at an exercise price of SEK 0.66 per share.

If all warrants series TO2 are exercised, the Company will receive approximately SEK 5.7 million before issuing costs. In order for the warrants not to expire and lose their value, it is required that the holder actively subscribes for new shares no later than August 25, 2023, or sells the warrants no later than August 22, 2023. Please observe that certain nominees might close their application earlier than August 25, 2023.

Summarized terms for warrants series TO2:
Exercise period: August 14 - August 25, 2023.
Issue size: 8,595,531 warrants series TO2, which entitle to subscription of 8,595,531 shares. If all warrants are exercised, the Company will receive approximately SEK 5.7 million before issuing costs.
Subscription price: SEK 0.66 per share.
Last day for trading warrants series TO2: August 22, 2023.

Share capital and dilution: If all warrants are exercised, the share capital will increase with SEK 214,888.275, from SEK 1,060,691.500 to SEK 1,275,579.775, and the number of shares and votes in the Company will increase with 8,595,531, from 42,427,660 to 51,023,191. In the event that all warrants series TO2 are exercised, the dilution amounts to approximately 16.8 percent of the number of shares and votes in the Company.

Please note that warrants that are not exercised no later than August 25, 2023, or sold no later than August 22, 2023, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

How warrants are exercised:

Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Note that the nominees need your notification of the exercise of warrants series TO2 in time before the end of the exercise period. Please contact your nominee for additional information. Observe that certain nominees might close their application earlier than August 25, 2023.

Direct-registered warrants (Securities account)
The warrant holders who have warrants series TO2 in a VP-account subscribe directly via an application form. The application form is then to be submitted via e-mail to emissioner@mangold.seor by mail according to instructions on the application form. Please contact the institute where you have your warrants registered for additional information.

The application form including instructions for payment will be available at the Company's website, www.Biosergen.net.

Advisors
Mangold Fondkommission AB is the financial advisor and Setterwalls Advokatbyrå AB is the legal advisor to Biosergen in connection with the exercise of warrants series TO2.